These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17435425)

  • 1. Value-based medicine and interventions for macular degeneration.
    Brown MM; Brown GC; Brown H
    Curr Opin Ophthalmol; 2007 May; 18(3):194-200. PubMed ID: 17435425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
    Brown MM; Brown GC; Brown HC; Irwin B; Brown KS
    Curr Opin Ophthalmol; 2008 May; 19(3):202-7. PubMed ID: 18408494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.
    Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
    Trans Am Ophthalmol Soc; 2007; 105():160-9; discussion 169-71. PubMed ID: 18427606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
    Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The burden of age-related macular degeneration: a value-based analysis.
    Brown MM; Brown GC; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic approaches to age-related macular degeneration today.
    Bressler NM
    Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to interpret a healthcare economic analysis.
    Brown MM; Brown GC
    Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neovascular age-related macular degeneration: past, present and future directions.
    Smith BT; Joseph DP; Grand MG
    Curr Opin Ophthalmol; 2007 May; 18(3):240-4. PubMed ID: 17435433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of predominantly classic, minimally classic, and occult subgroups in exudative age-related macular degeneration.
    Shah AR; Del Priore LV
    Ophthalmology; 2009 Oct; 116(10):1901-7. PubMed ID: 19592101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence.
    Virgili G; Do DV; Bressler NM; Menchini U
    Acta Ophthalmol Scand; 2007 Feb; 85(1):6-20. PubMed ID: 17244204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Macular translocation - a therapeutic approach for neovascular macular degeneration in the era of anti-VEGF therapy?].
    Ziemssen F; Gelisken F
    Klin Monbl Augenheilkd; 2009 Jan; 226(1):31-7. PubMed ID: 19173161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM; Richard G; Augustin A; Aylward WG; Bandello F; Corcòstegui B; Cunha-Vaz J; Gaudric A; Leys A; Schlingemann RO;
    Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
    Mantel I; Zografos L; Ambresin A
    Ophthalmologica; 2008; 222(5):321-3. PubMed ID: 18617755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autofluorescence imaging in age-related macular degeneration complicated by choroidal neovascularization: a prospective study.
    Vaclavik V; Vujosevic S; Dandekar SS; Bunce C; Peto T; Bird AC
    Ophthalmology; 2008 Feb; 115(2):342-6. PubMed ID: 17599415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.